Get to know our clinical trials
A PHASE III OPEN-LABEL STUDY COMPARING THE EFFICACY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH (POLA-R-CHP) VERSUS POLA-R-C.
EL OBJETIVO DE ESTE ESTUDIO ES COMPARAR LOS EFECTOS, BUENOS O MALOS, DE GLOFITAMAB CON POLA-R-CHP FRENTE A POLA-R-CHP SOLO EN PACIENTES CON LCBG, PARA AVERIGUAR CUÁL DE ELLOS ES MEJOR
Technical Summary
- ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO Y ABIERTO PARA COMPARAR LA EFICACIA Y LA SEGURIDAD DE GLOFITAMAB (RO7082859) EN COMBINACIÓN CON POLATUZUMAB VEDOTINA MÁS RITUXIMAB, CICLOFOSFAMIDA, DOXORUBICINA Y PREDNISONA (POLA-R-CHP) FRENTE A POLA?R?CHP EN PACIENTES CON LINFOMA DE CÉLULAS B GRANDES NO TRATADO PREVIAMENTE
- Code EudraCT: 2023-504028-24-00
- Protocol number: GO44145
- Promoter: F. Hoffmann-La Roche Ltd.
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.